Overview

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Status:
Completed

Trial end date:
2017-11-28

Target enrollment:

Participant gender:

Summary

The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Angiopeptin
Lanreotide
Somatostatin